Geron (GERN) EPS (Diluted) Growth (3y) (2016 - 2026)
Powered by 
Analysis
Geron (GERN) EPS (Diluted) Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.35% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -130.36% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.01% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.90% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 82.91% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.39% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -45.62% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 34.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.84% |
| Mar 31, 2026 | 57.58% |
| Dec 31, 2025 | 27.26% |
| Sep 30, 2025 | 35.27% |
| Jun 30, 2025 | 30.31% |
| Mar 31, 2025 | 31.54% |
| Dec 31, 2024 | 27.96% |
| Sep 30, 2024 | 21.04% |
| Jun 30, 2024 | -4.44% |
| Mar 31, 2024 | 5.00% |
| Dec 31, 2023 | -1.39% |
| Sep 30, 2023 | 14.56% |
| Jun 30, 2023 | 4.52% |
| Mar 31, 2023 | 13.38% |
| Dec 31, 2022 | 14.98% |
| Sep 30, 2022 | -2.37% |
| Jun 30, 2022 | 8.56% |
| Mar 31, 2022 | -10.07% |
| Dec 31, 2021 | -22.18% |
| Sep 30, 2021 | -30.47% |